HB 1189 passed the House on January 29, 2020. The bill was amended in the Senate on March 10, 2020, and returned to the House. The House concurred in the Senate amendment and subsequently passed the bill as amended on March 12, 2020.

Since the advent of genetic testing, there have been concerns about the use of personal genetic information by third parties. In particular, there is a concern that insurers may discriminate against individuals who have genetic markers indicating a heightened risk of developing certain diseases or health conditions.

The federal Health Insurance Portability and Accountability Act of 1996 prohibits health insurers from making coverage decisions solely based on personal genetic information. The federal Genetic Information Nondiscrimination Act of 2008 extended this concept by prohibiting health insurers from using genetic information in the underwriting process, and in the setting of premiums. Florida law prohibits health insurers from considering genetic information, both when issuing insurance policies and when setting applicable premium rates. This prohibition, however, does not extend to issuers of life insurance, long-term care insurance, and disability income insurance policies.

The bill expands existing state prohibitions on the use of genetic information by insurers to include entities that issue policies for life insurance, long-term care insurance, and disability income insurance. Specifically, the bill prohibits issuers of life insurance, long-term care insurance, and disability income insurance from canceling, limiting, or denying coverage, and from setting different premium rates, based on personal genetic information without a specific diagnosis related to the genetic information. The bill also prohibits these insurers from requiring or soliciting genetic information, using genetic test results, or considering a person's decisions or actions relating to genetic testing for any insurance purpose.

The bill expressly provides that it may not be construed to prevent life insurers or long-term care insurers from accessing an individual's medical record as part of an application process. Likewise, it provides that nothing in the bill prevents a life insurer or long-term care insurer from considering a medical diagnosis included in an applicant's medical record, even if a diagnosis resulted from the use of a genetic test.

The bill has no fiscal impact on state or local government.

The bill was approved by the Governor on June 30, 2020, ch. 2020-162, L.O.F., and will take effect on July 1, 2020.
I. SUBSTANTIVE INFORMATION

A. EFFECT OF CHANGES:

Background

Regulation of Insurance in Florida

The Office of Insurance Regulation (OIR) regulates insurers, including life, health, and long-term care insurers, under the Florida Insurance Code. Parts III and V of ch. 627, F.S., specifically address life insurers. Part VI of ch. 627, F.S. specifically addresses health insurers. The Agency for Healthcare Administration (AHCA) regulates the quality of care provided by health maintenance organizations (HMOs) under part III of ch. 641, F.S., and part I of ch. 641, F.S., focuses on OIR’s regulatory role of HMOs. Before receiving a certificate of authority from OIR, an HMO must receive a health care provider certificate from AHCA. Part XVIII of ch. 627, F.S., specifically addresses long-term care insurance, which is coverage for medical and personal care services provided in a setting other than an acute care unit of a hospital.

Genetic Testing

The availability and use of genetic tests has increased dramatically in recent years. As of March 2017, there were nearly 70,000 genetic testing products on the market, with an average of 10.6 new testing products entering the market a day from 2015 to 2017. A 2016 survey indicated that 5.5 percent of adults in the U.S. had undergone genetic testing. Over half of those tested did so based on a concern about future health problems for them or their children, while 18 percent were tested to learn more about family heritage. The U.S. Centers for Disease Control and Prevention (CDC) recognizes the development of genomic tests for thousands of diseases and health conditions, while also acknowledging that such tests are not necessarily a conclusive indication that an individual will develop a particular disease or condition.

A wide range of health-related DNA screenings are available. The National Institutes for Health (NIH) categorizes these tests as follows.

- **Diagnostic testing** - identifies a genetic condition or disease that is making or in the future will make a person ill. The results of diagnostic testing can help in treating and managing the disorder.
- **Predictive and pre-symptomatic genetic testing** - identifies genetic variations that increase a person’s chance of developing specific diseases. This type of genetic testing may help provide information about a person’s risk of developing a disease, and can help in decisions about lifestyle and health care.

---

2 Ss. 641.21(1) and 641.48, F.S.
• **Carrier testing** – identifies whether a person “carries” a genetic change that can cause a disease. Carriers usually show no signs of the disorder; however, they can pass on the genetic variation to their children, who may develop the disorder or become carriers themselves.

• **Prenatal testing** - identifies fetuses that have certain diseases.

• **Pre-implantation genetic testing** – identifies whether embryos for implantation carry genes that could cause disease. This is often done in conjunction with *in vitro* fertilization.

• **Newborn screening** - is used to test babies one or two days after birth to determine if those newborns have certain diseases known to cause problems with health and development.

• **Pharmacogenetic testing** - provides information about how certain medicines are processed in a person’s body. This type of testing can help a healthcare provider choose the medicines that work best with a person’s genetic makeup. For example, genetic testing is now available to guide treatments for certain cancers.

• **Research genetic testing** – helps scientists learn more about how genes contribute to health and disease, as well as develop gene-based treatments. Sometimes the results do not directly help the research participant, but they may benefit others in the future by helping researchers expand their understanding of the human body.

One often-cited use of genetic testing involves screening of female patients for a gene mutation that can be an early predictor of breast cancer. *BRCA 1* and *BRCA 2* gene mutations are relatively rare, but women having these mutations develop breast cancer at much higher rates than those without. BRCA testing has become increasingly prevalent among women in families with histories of breast cancer.

Use of Personal Genetic Information in Insurance Markets

The now-widespread availability of genetic tests has given rise to questions and concerns over the appropriate use of genetic information. While an individual may voluntarily submit to genetic testing in an effort to gain insights into his or her own genetic history, third parties may seek to obtain this same information for other purposes, such as for use in insurance markets.

For example, insurers might use genetic information to exclude high-risk individuals from established risk pools. Insurers might also charge higher premium rates to an individual whose genetic information indicates that the individual is at an increased risk of developing a degenerative health condition. Conversely, exclusion of higher-risk insureds could reduce premium inflation for those left in the risk pool.

Similarly, consumers could use personal genetic information to the detriment of insurers. For example, an individual may discover through genetic testing that he or she is likely to develop a serious health condition, and only then purchase life insurance. An insurer is at a disadvantage and cannot accurately gauge the risk posed by covering an individual in this situation. Adverse selection of this nature could destabilize insurance markets if access to personal genetic information leads to widespread

---


9 Id.


11 Id.

12 Adverse selection is defined as an imbalance in an exposure group created when persons who perceive a high probability of loss for themselves seek to buy insurance to a much greater degree than those who perceive a low probability of loss. IRMI, [https://www.irmi.com/term/insurance-definitions/adverse-selection](https://www.irmi.com/term/insurance-definitions/adverse-selection) (last accessed March 11, 2020).
changes in consumer behavior. Specifically, the risk-spreading ability of insurance could be compromised if only those who are likely to become ill purchase insurance.

While the specific information provided by the genetic testing industry regarding medical conditions and their associated risks is limited at present, it is rapidly evolving. In 2013, the United States Food and Drug Administration (FDA) instructed 23andMe to stop giving health information to consumers. However, by 2018, 23andMe received approval from the FDA to provide reports regarding certain health conditions or risks, including the genetic variants in the BRCA 1 and BRCA 2 genes. Other vendors also provide lists of genetic variants, available to consumers, with information regarding the scientific significance of each variant. In the future, consumers may be able to take the ever-evolving information provided by genetic testing, compare it to the information provided by these vendors, and determine they have a genetic condition or disease, or are likely to develop a health condition. Based upon this determination, they may decide to purchase insurance they otherwise would not, without disclosing the results of their genetic testing, and thereby receive the insurance at a rate that is actuarially unsound for their true risk class.

Federal Laws

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) includes the first federal regulations on the use of personal genetic information. HIPAA prohibits health insurers from using “preexisting condition” exclusions based solely on an individual’s genetic information. Under HIPAA, insurers can make coverage decisions using information reflecting diagnosed health conditions, but not based on genetic indicators alone.

The Genetic Information Nondiscrimination Act of 2008 (GINA) extended federal patient protections by preventing health insurers from using genetic information in the underwriting of health insurance products. Health insurers may not charge higher premiums or make coverage decisions based solely on an individual’s genetic information. However, the prohibitions outlined in GINA do not extend to other types of insurance, such as life insurance and long-term care insurance. There are currently no federal limitations on the use of genetic information by these insurers.

The federal Patient Protection and Affordable Care Act (PPACA) prohibits most individual and group health insurers from excluding coverage to or otherwise discriminating against persons with pre-existing or complex health conditions. Moreover, the law prohibits plans from using most forms of medical underwriting, which had previously been used to link personal health status to the cost and availability of health insurance.

State Laws

14 Id.
16 Id.
17 Id.
19 Id.
22 42 U.S.C. 300gg. The law allows insurers to consider an individual’s age and tobacco use in the development of applicable rates. However, virtually all other underwriting is prohibited.
States have adopted various regulations related to the use of genetic information by insurers. In general, states address patient privacy for personal genetic information by:

1. Requiring informed consent before performing genetic testing;
2. Restricting the use of genetic data by health insurance, employers or providers of long-term life care or insurance; and,
3. Limiting disclosure of the personal genetic information without the consent of the individual or defining genetic data as the ‘property’ of the individual.

Most states have enacted laws that prohibit genetic discrimination by health insurers. A number of states have taken actions to limit or prohibit the use of genetic information in other lines of insurance as well. For example, Arizona, California, Massachusetts and New Jersey restrict use of genetic information by life insurers, and Kansas, Maryland and Massachusetts restrict use by long-term care insurers. Similarly, Arizona, California, Idaho, Kansas, Massachusetts and New Jersey restrict use by disability insurers.

**Florida Law**

Section 760.40, F.S., makes the results of genetic testing the exclusive personal property of the person tested, and makes it a first degree misdemeanor to sharing test results without the informed consent of the person tested.

Section 627.4301, F.S., prohibits health insurers from considering genetic information, both when issuing insurance policies and when setting applicable premium rates. Insurers cannot require or solicit genetic information, or employ underwriting based on the results of any genetic testing that an individual may choose to complete, and cannot use such results for any purpose. This prohibition is currently limited to self-insured health plans, fully-insured health plans, HMOs, prepaid limited health service organizations, prepaid health clinics, fraternal benefit societies, or any other health care arrangement where risk is assumed. This section of law expressly exempts several forms of insurance from the prohibition: life insurance, disability income, long-term care, accident-only, hospital indemnity or fixed indemnity, dental, and vision.

**Effect of Proposed Changes**

The bill amends s. 627.4301, F.S., existing prohibitions on the use of genetic information by insurers to include entities that issue policies for life insurance, long-term care insurance, and disability income insurance. Specifically, the bill prohibits issuers of life insurance, long-term care insurance, and disability income from canceling, limiting, or denying coverage, and from setting different premium rates, based on personal genetic information without a specific diagnosis related to the genetic information. The bill also prohibits life insurers and long-term care insurers from requiring or soliciting

---

25 The National Human Genome Human Research Institute maintains a searchable database of legislation related to genetic information that has either been enacted or considered by state legislatures. U.S. Department of Health and Human Services, National Institutes of Health – National Human Genome Research Institute, Genome Statute and Legislation Database, available at https://www.genome.gov/policyethics/legdatabase/pubsearch.cfm?CFID=22285441&CFTOKEN=7fc536f1b99bd21-2342A48B-03C6-03BE-03FE2F39A8695C0F (last accessed March 11, 2020).
27 Supra note 19.
28 See also s. 626.9706, F.S., which prohibits insurers from refusing coverage or charging higher premiums to individuals determined to carry the sickle-cell trait.
29 Florida law does not define “diagnosis.” However, “diagnosis” is generally defined as the “art or act of identifying a disease from its signs and symptoms.” Merriam-Webster, https://www.merriam-webster.com/dictionary/diagnosis (last accessed March 11, 2020).
genetic information, using genetic test results, or considering a person’s decisions or actions relating to genetic testing for any insurance purpose.

The bill expressly provides that it may not be construed to prevent life insurers or long-term care insurers from accessing an individual’s medical record as part of an application process. Likewise, it expressly states that nothing in the bill prevents a life insurer or long-term care insurer from considering a medical diagnosis included in an applicant’s medical record, even if a diagnosis resulted from the use of a genetic test.

The bill applies to insurance policies entered into or renewed on or after January 1, 2021.

Subject to the Governor’s veto powers, the bill takes effect on July 1, 2020.

II. FISCAL ANALYSIS & ECONOMIC IMPACT STATEMENT

A. FISCAL IMPACT ON STATE GOVERNMENT:
   1. Revenues:
      None.
   2. Expenditures:
      None.

B. FISCAL IMPACT ON LOCAL GOVERNMENTS:
   1. Revenues:
      None.
   2. Expenditures:
      None.

C. DIRECT ECONOMIC IMPACT ON PRIVATE SECTOR:
   It is unclear whether or how, issuers of life insurance and long-term care insurance are currently using personal genetic information, so the economic impact of the bill’s prohibition on its use is unknown.

D. FISCAL COMMENTS:
   None.